Timber pharmaceuticals receives court approval of all “first day” motions to support business operations & discloses communication from nyse american

Warren, nj, nov. 28, 2023 (globe newswire) -- via newmediawire – timber pharmaceuticals, inc. (nyse american: tmbr), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-in-possession ("timber" or the "company"), today announced that all "first day" motions related to the company's voluntary chapter 11 petitions for reorganization filed on november 17, 2023, were approved on an interim basis by the u.s. bankruptcy court for the district of delaware.
TMBR Ratings Summary
TMBR Quant Ranking